HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (Papers in Press[PDF]) All Versions of this Article: jmm.0.011122-0v1 58/8/977    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Google Scholar Articles by Oyston, P. C.F. Articles by Clark, G. C. PubMed PubMed Citation Articles by Oyston, P. C.F. Articles by Clark, G. C. Agricola Articles by Oyston, P. C.F. Articles by Clark, G. C.

Novel peptide therapeutics for treatment of infections

Dstl Porton Down

¹ E-mail: pcoyston{at}dstl.gov.uk

Received March 16, 2009
Accepted April 30, 2009

As antibiotic resistance increases world-wide, there is an increasing pressure to develop novel classes of antimicrobial compounds to fight infectious disease. Peptide therapeutics represent a novel class of therapeutic agents, many of which have been identified from studies of innate immune effector proteins, such as cationic antimicrobial peptides and peptidoglycan recognition proteins. Licensed products are currently limited to exploitation of natural products for topical applications. However, research using new approaches to identify novel antimicrobial peptide therapeutics, and new approaches to delivery and improving stability will result in an increased range of peptide therapeutics available in the clinic for broader applications.